Lithera beta agonist begins trial as fat-buster

03/19/2013 | Xconomy

Lithera announced the launch of a 500-patient, Phase II trial of an injectable version of salmeterol xinafoate for localized reduction of abdominal fat tissue. The selective beta agonist is approved in aerosol form as an inhaled asthma treatment.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI